A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination with Tremelimumab in Participants with Selected, Advanced Solid Tumors
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (Non-small Cell Lung Cancer)
Sponsor: GlaxoSmithKline
Enrolling: Male and Female Patients
IRB Number: AAAS1028
U.S. Govt. ID: NCT03693612
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study is being done to test the combination of two new drugs, GSK3359609 and Tremelimumab, in certain cancers. These two drugs are experimental which means they have not been fully tested yet and are not yet approved to treat any disease. There are two parts to this study. Part 1 determines the best dose for the study drugs and part 2 compares the study drugs to what is currently available.
This study is closed
Investigator
Brian Henick, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a confirmed diagnosis of non-small cell lung cancer? Yes No
Have you received prior therapy for your cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE